Compare CWCO & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWCO | BNTC |
|---|---|---|
| Founded | 1973 | 1995 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 454.2M |
| IPO Year | 1997 | 2020 |
| Metric | CWCO | BNTC |
|---|---|---|
| Price | $29.32 | $11.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $40.00 | $27.67 |
| AVG Volume (30 Days) | 91.1K | ★ 120.0K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.73% | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $132,073,368.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $42.86 | N/A |
| P/E Ratio | $127.39 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $28.17 | $9.85 |
| 52 Week High | $39.12 | $16.76 |
| Indicator | CWCO | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 40.83 |
| Support Level | $29.18 | $11.40 |
| Resistance Level | $30.69 | $13.48 |
| Average True Range (ATR) | 0.50 | 0.71 |
| MACD | 0.09 | -0.25 |
| Stochastic Oscillator | 77.19 | 19.99 |
Consolidated Water Co Ltd is a water utility company. It develops and operates seawater desalination plants and water distribution systems. The company's business segments are; The retail segment operates the water utility for the Seven Mile Beach and West Bay areas of Grand Cayman Island, The bulk segment supplies potable water to government utilities in Grand Cayman and The Bahamas under long-term contracts, The services segment designs, constructs and sells water infrastructure and provides management and operating services to third parties. The manufacturing segment manufactures and services a wide range of custom and specialized water-related products applicable to commercial, municipal, and industrial water production, supply, and treatment, and the corporate segment.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.